<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02408536</url>
  </required_header>
  <id_info>
    <org_study_id>MITO 22</org_study_id>
    <nct_id>NCT02408536</nct_id>
  </id_info>
  <brief_title>Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer</brief_title>
  <acronym>MITO 22</acronym>
  <official_title>Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to retrospectively evaluate treatments and outcomes of patients
      with low grade serous ovarian carcinomas in Italy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>risk of recurrence in patients with low-grade serous ovarian carcinoma</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of patients with objective tumor response after receiving chemotherapy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of patients with objective tumor response after receiving hormone therapy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number of patients with objective tumor response after receiving combination hormonal and chemotherapy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Low-grade Serous Ovarian Carcinoma</condition>
  <condition>Recurrent Invasive Borderline Serous Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Single cohort</arm_group_label>
    <description>Retrospective analysis of all patients diagnosed, from 01/01/2000 to 01/01/2014, with low-grade serous ovarian cancer or invasive recurrence after surgery for borderline serous carcinoma</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Archival tissue tumor samples in paraffin blocks for evaluation of diagnosis and biomarkers
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients diagnosed, from 01/01/2000 to 01/01/2014, with low-grade serous ovarian carcinoma
        or with invasive recurrence after surgery for borderline serous carcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis low-grade serous ovarian carcinoma

          -  OR invasive recurrence after surgical resection of borderline serous ovarian carcinoma

          -  Availability of archival tumor specimen (paraffin embedded block) for central analysis
             and evaluation for mutations

          -  Age &gt; 18 years

          -  Signed informed consent

        Exclusion Criteria:

          -  High-grade serous, mucinous, endometrioid, or any other non-low-grade serous ovarian
             carcinoma

          -  Unavailability of archival tumor specimen
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandro Pignata, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chiara Della Pepa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Perrone, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI Naples</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Perrone, MD PhD</last_name>
    <phone>+39 081 5903571</phone>
    <email>datamanager@usc-intnapoli.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Teresa Ribecco, PhD</last_name>
    <phone>+39 081 5903619</phone>
    <email>teresa.ribecco@usc-intnapoli.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istitute Nazionale Tumori - Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2015</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chemotherapy</keyword>
  <keyword>hormone therapy</keyword>
  <keyword>borderline</keyword>
  <keyword>low-grade</keyword>
  <keyword>serous ovarian cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

